Drug profile
Binimetinib
GenericRadar assessment
Patent Radar Assessment
Grade C1
United States · 2030 Radar
Verification
HIGH
Why not A?
Not Grade A: the 2030 MEKTOVI patents US9850229 and US10005761 are method-of-use patents. The compound/composition Drug Substance/Drug Product patent US7777050 reaches its protection endpoint earlier.
Core Patent Expiry
2026-03-13
2030 Target Event
US9850229
Method of Use · 2030-08-27
Core API Event?
No
Later Blocking Patents
Yes. Additional MEKTOVI patent events continue beyond 2030, including 2031 and 2033.
Generic Entry Assessment
2030 is an indication/combination-use event rather than an API cliff. Generic entry analysis should consider skinny-label possibilities and combination-treatment claims.
Patent landscape
| Country | Patent no. | Type | Expiry | Status | Verified | Opportunity |
|---|---|---|---|---|---|---|
| United States | US9850229 | Method of Use | 2030-08-27 | Protected | Yes | 41 |
API sourcing
Regulatory filing labels distinguish verified/listed records from records that have not yet been verified. “Not verified” does not mean that a filing does not exist.
| API | Manufacturer | Country | US DMF | KDMF | Japan MF | CEP | EU GMP | Status |
|---|---|---|---|---|---|---|---|---|
| Binimetinib | No supplier linked | — | — | — | — | Not verified | — |